• Confocal imaging of U-2 OS cells using [KD Validated] ISG15 Rabbit monoclonal antibody (STJ11101824, dilution 1:100) (Red). The cells were counterstained with Alpha-Tubulin Mouse monoclonal antibody (dilution 1:400) (Green). DAPI was used for nuclear staining (blue). Objective: 100x.
  • Western blot analysis of lysates from wild type (WT) and ISG15 Rabbit monoclonal antibody knockdown (KD) Hela (KD) cells, using [KD Validated] ISG15 Rabbit monoclonal antibody (STJ11101824) at 1:510 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (STJS000856) at 1:10000 dilution. Lysates/proteins: 25 Mu g per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 60s.

Anti-ISG15 antibody (1-165) [S4MR] (STJ11101824)

SKU:
STJ11101824

£146.50 - £639.50
Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB/IF
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit monoclonal antibody anti-ISG15 (1-165) is suitable for use in Western Blot and Immunofluorescence research applications.
Clonality: Monoclonal
Clone ID: S4MR
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.05% Proclin300, 0.05% BSA, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:500-1:2000
IF/ICC 1:50-1:200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: ISG15
Gene ID: 9636
Uniprot ID: ISG15_HUMAN
Immunogen Region: 1-165
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-165 of human ISG15 (NP_005092.1).
Immunogen Sequence: MGWDLTVKMLAGNEFQVSLS SSMSVSELKAQITQKIGVHA FQQRLAVHPSGVALQDRVPL ASQGLGPGSTVLLVVDKCDE PLSILVRNNKGRSSTYEVRL TQTVAHLKQQVSGLEGVQDD LFWLTFEGKPLEDQLPLGEY GLKPLSTVFMNLRLRGGGTE PGGRS
Tissue Specificity Detected in lymphoid cells, striated and smooth muscle, several epithelia and neurons. Expressed in neutrophils, monocytes and lymphocytes. Enhanced expression seen in pancreatic adenocarcinoma, endometrial cancer, and bladder cancer, as compared to non-cancerous tissue. In bladder cancer, the increase in expression exhibits a striking positive correlation with more advanced stages of the disease.
Post Translational Modifications S-nitrosylation decreases its dimerization, thereby increasing the availability as well as the solubility of monomeric ISG15 for its conjugation to cellular proteins. Induced as an inactive, precursor protein that is cleaved by specific proteases to expose the C-terminal diglycine (LRLRGG) motif. This motif is essential not only for its conjugation to substrates but also for its recognition by the relevant processing proteases.
Function Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Isgylation of the viral sensor IFIH1/MDA5 promotes IFIH1/MDA5 oligomerization and triggers activation of innate immunity against a range of viruses, including coronaviruses, flaviviruses and picornaviruses. Can also isgylate: EIF2AK2/PKR which results in its activation, RIGI which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade thereby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity. The secreted form acts through the integrin ITGAL/ITGB2 receptor to initiate activation of SRC family tyrosine kinases including LYN, HCK and FGR which leads to secretion of IFNG and IL10.the interaction is mediated by ITGAL.
Protein Name Ubiquitin-Like Protein Isg15
Interferon-Induced 15 Kda Protein
Interferon-Induced 17 Kda Protein
Ip17
Ubiquitin Cross-Reactive Protein
Hucrp
Database Links Reactome: R-HSA-1169408
Reactome: R-HSA-168276
Reactome: R-HSA-168928
Reactome: R-HSA-5656169
Reactome: R-HSA-909733
Reactome: R-HSA-936440
Reactome: R-HSA-9705671
Cellular Localisation Cytoplasm
Secreted
Exists In Three Distinct States: Free Within The Cell
Released Into The Extracellular Space
Or Conjugated To Target Proteins
Alternative Antibody Names Anti-Ubiquitin-Like Protein Isg15 antibody
Anti-Interferon-Induced 15 Kda Protein antibody
Anti-Interferon-Induced 17 Kda Protein antibody
Anti-Ip17 antibody
Anti-Ubiquitin Cross-Reactive Protein antibody
Anti-Hucrp antibody
Anti-ISG15 antibody
Anti-G1P2 antibody
Anti-UCRP antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance